Kyverna Therapeutics Inc. Common Stock (KYTX)
Stock · NASDAQ · Health Care
$5.68as of 10/16/2026
Price chart
Active signals
KYTX Signal Track Record
How signals performed across all stocks →What KYTX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 15 | +2.5% | 53% | September 24, 2026 |
| Bollinger Band Breakout | 13 | -15.3% | 23% | August 17, 2026 |
| Bollinger Band Breakdown | 6 | -14.5% | 17% | September 9, 2026 |
| 200-Day Moving Average TouchActive now | 4 | +17.5% | 75% | August 21, 2026 |
| Any 20-session window (baseline) | -0.1% | 50% |
Computed by MarketWall from daily closing prices since November 22, 2024. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About KYTX
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole bl…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 149
- Website
- kyvernatx.com/
Fundamentals
- 1-day range
- $5.67$6.02
- Market cap
- $471.16M
- P/E (trailing)
- —
- P/E (forward)
- -1.88
- EPS (trailing)
- $-2.94
- Dividend yield
- —
- Beta
- 2.12
- Avg. volume
- 847.0K
Forecasts
5 analyst ratings
Kyverna Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- KYTXKyverna Therapeutics Inc. Common Stock$5.67▼ 5.03%Market cap $471.16MP/E —$5.61$13.67
- VALNValneva SE American Depositary Shares$5.61▼ 5.08%Market cap $491.51MP/E —$2.03$5.15
- CABACabaletta Bio Inc. Common Stock$1.41▼ 9.03%Market cap $450.03MP/E —$1.51$4.23
- PROKProKidney Corp. Class A Ordinary Shares$1.33▼ 8.59%Market cap $495.38MP/E —$1.3$3.48
- EIKNEikon Therapeutics Inc. Common Stock$7.42▼ 1.59%Market cap $498.62MP/E —$6.45$17.4
- OCGNOcugen Inc. Common Stock$0.78▼ 4.18%Market cap $420.50MP/E —$0.785$2.73
- DNAGinkgo Bioworks Holdings Inc. Class A Common Stock$10.27▼ 12.67%Market cap $528.15MP/E —$5.37$18.22
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| KYTX Kyverna Therapeutics Inc. Common Stock | $471.16M | — | $5.67 | ▼ 5.03% | $5.61$13.67 |
| VALN Valneva SE American Depositary Shares | $491.51M | — | $5.61 | ▼ 5.08% | $2.03$5.15 |
| CABA Cabaletta Bio Inc. Common Stock | $450.03M | — | $1.41 | ▼ 9.03% | $1.51$4.23 |
| PROK ProKidney Corp. Class A Ordinary Shares | $495.38M | — | $1.33 | ▼ 8.59% | $1.3$3.48 |
| EIKN Eikon Therapeutics Inc. Common Stock | $498.62M | — | $7.42 | ▼ 1.59% | $6.45$17.4 |
| OCGN Ocugen Inc. Common Stock | $420.50M | — | $0.78 | ▼ 4.18% | $0.785$2.73 |
| DNA Ginkgo Bioworks Holdings Inc. Class A Common Stock | $528.15M | — | $10.27 | ▼ 12.67% | $5.37$18.22 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Kyverna Therapeutics To Demonstrate Two Abstracts For Presentation At MSToronto2026 10th Joint ACTRIMS-ECTRIMS Meetingbenzinga · 10/7/2026
- Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026Yahoo · 10/7/2026
- Kyverna Therapeutics To Demonstrate Two Abstracts For Presentation At MSToronto2026 10th Joint ACTRIMS-ECTRIMS MeetingBenzinga · 10/7/2026
- BioMarin Appoints Cara Bauer as Chief People OfficerYahoo · 10/5/2026
- KYTX Stock Reverses Gains After One-Year Cell Therapy Trial Data — But CEO Says Disease Burden Justifies A Premium PriceYahoo · 9/24/2026
- Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data and Longer-Term Follow-Up for SPS and GMG Trials - SlideshowSeekingAlpha · 9/24/2026
- Kyverna stock jumps on positive one-year therapy dataYahoo · 9/24/2026
- Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data and Longer-Term Follow-Up for SPS and GMG Trials TranscriptSeekingAlpha · 9/24/2026
- Kyverna Therapeutics Therapy Delivers Sustained Relief in Rare Neurological ConditionsBenzinga · 9/24/2026
Insider Activity
Insider Actions →- Mert Aktar · May 27, 2026 · Grant20.6K
- Christi Shaw · May 27, 2026 · Tax Withholding4.2K @ $8.59
- Fred E. Cohen · May 27, 2026 · Grant5.1K
- Ian T. Clark · May 27, 2026 · Grant20.6K
- Ian T. Clark · May 27, 2026 · Grant5.1K
- Beth C. Seidenberg · May 27, 2026 · Grant20.6K
- Beth C. Seidenberg · May 27, 2026 · Grant5.1K
- Mert Aktar · May 27, 2026 · Grant5.1K
- Fred E. Cohen · May 27, 2026 · Grant20.6K
- Dac Nadia · May 4, 2026 · Grant300.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 34.69M
- Total value held
- $285.87M
- Institutional holders
- 108
- Unknown4.24M
- Unknown4.13M
- Unknown3.11M
- Unknown2.00M
- Unknown2.00M
- Unknown1.78M
- Unknown1.56M
- Unknown1.13M
- Unknown1.01M
- Unknown989.1K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Kyverna Reports Positive One-Year Data for Miv-cel Trials
Kyverna Therapeutics disclosed one‑year data from its Miv‑cel trials in stiff person syndrome and generalized myasthenia gravis, showing durable responses and a favorable safety profile. The CEO noted that the high disease burden supports a premium pricing strategy. These results reinforce the potential of a single‑dose therapy to reduce long‑term treatment burden.
Kyverna Reports Positive One-Year Data for Miv-cel Trials. Kyverna Therapeutics disclosed one‑year data from its Miv‑cel trials in stiff person syndrome and generalized myasthenia gravis, showing durable responses and a favorable safety profile. The CEO noted that the high disease burden supports a premium pricing strategy. These results reinforce the potential of a single‑dose therapy to reduce long‑term treatment burden.